the first half of the year is likely to be challenging for massimo. it until we get a pullback since there's absolutely no rush. for now the thing to do, how about nothing? then on january 26th richard in virginia called me about a stock i'm asked about a lot of times on the street. ziopharm oncology. teency tiny super speculative biotech company. market cap of less than a million. i don't like to talk about the real small guys. no drugs on the market. developing a drug for fighting cancer. has a promising treatment for soft tissue sarcomba and it is in phase 3 development. last phase. i have a lot of caveats here. since you're basically playing fda roulette with this one, you know i don't like that game, stock is totally dependent on binary fda decisions. proceed with caution. maximum homework. not for the faint of heart. finally on january 30th casey from oregon asked me about guidewire. gwre. which sells enterprise software and services to property and casualty insurers. guidewire's a fresh-faced ipo that just came public on january 25th at $13 a s